Senescence-associated reprogramming induced by interleukin-1 impairs response to EGFR neutralization

Area of Science:

• Oncology
• Molecular Biology
• Cancer Research

Background:

• Epidermal Growth Factor Receptor (EGFR) targeting is a primary strategy for metastatic colorectal cancer (mCRC).
• Patients with wild-type KRAS and BRAF benefit from anti-EGFR monoclonal antibodies (moAbs) like cetuximab (CTX), but acquired resistance limits long-term efficacy.
• Interleukin-1 (IL-1) has been associated with reduced sensitivity to CTX, but its precise role in mediating resistance remains unclear.

Discussion:

• IL-1 induces a G0 phase arrest in sensitive colorectal cancer (CRC) cells under CTX treatment.
• CTX-resistant CRC cells exhibit sustained IL-1R1 expression and post-senescence reprogramming, evidenced by increased SNAIL expression.
• IL-1 appears to mediate resistance through a trans-regulatory mechanism on EGFR signaling, establishing senescence and regulating EGFR activity.

Key Insights:

• Upregulation of IL-1R1 and a senescence program occur in CRC cells under CTX treatment.
• IL-1 blockade using a recombinant decoy can re-sensitize resistant CRC cells by inducing senescence and halting proliferation.
• IL-1 plays a critical role in establishing drug resistance by modulating EGFR signaling pathways.

Outlook:

• Combined blockage of IL-1R and EGFR presents a promising therapeutic strategy.
• Restoring sensitivity to EGFR-targeting moAbs in mCRC patients is a key goal.
• Further research into IL-1 mediated resistance mechanisms could reveal novel therapeutic targets.